Skip to main content

Table 2 Regression analysis for mortality at 28 days for CytoSorb-treated patients

From: Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study

VariablesUnivariable Full multivariable model (forced) Final multivariable model (bstep LR) 
OR (95% CI)pOR (95% CI)pOR (95% CI)p
Age per 10 years older1.99 (1.3–3.1)0.0021.64 (1.0–2.7)0.0501.67 (1.0–2.7)0.034
Female gender1.50 (0.6–4.0)0.412  
Body mass index0.96 (0.9–1.0)0.260  
SOFA admission1.20 (1.0–1.4)0.041  
SOFA at the start of treatment1.28 (1.1–1.6)0.0141.10 (0.8–1.4)0.505 
MAP admission0.99 (0.9–1.0)0.460  
MAP at the start of treatment0.96 (0.9–1.0)0.0510.99 (1.0–1.03)0.739 
Lactate admission1.07 (0.9–1.2)0.180  
Lactate at the start of treatment1.16 (1.0–1.3)0.0141.13 (1.0–1.3)0.1081.15 (1.0–1.3)0.031
Noradrenaline admission2.25 (0.8–6.0)0.106  
Noradrenaline treatment2.60 (1.2–5.9)0.0210.98 (0.3–2.8)0.973 
Noradrenaline duration1.02 (0.9–1.2)0.731  
Admission ICU to treatment0.88 (0.7–1.1)0.216  
Admission hospital to treatment0.98 (0.9–1.1)0.675  
Surgery0.37 (0.1–1.0)0.0550.43 (0.1–1.6)0.206 
Type of sepsis:   
Pneumosepsis3.52 (1.0–12.7)0.0542.83 (0.5–16.9)0.2545.47 (1.2–25.2)0.029
 Abdominal sepsis0.51 (0.2–1.3)0.171  
 Cutaneous sepsis0.27 (0.1–1.4)0.117  
 Vascular sepsis4.86 (0.5–46.0)0.168  
 Sepsis unknown cause2.36 (0.4–13.8)0.343  
History of:   
 Diabetes mellitus1.61 (0.5–5.3)0.432  
 Hypertension1.31 (0.5–3.6)0.601  
 COPD1.97 (0.4–9.0)0.380    
 Coronary artery disease0.86 (0.2–3.5)0.831  
 Heart failureNA0.999    
 Chronic kidney disease1.98 (0.4–9.0)0.380  
 Hemodialysis/peritoneal1.10 (0.1–18.3)0.949  
 CVA1.10 (0.2–5.9)0.908  
 Peripheral artery disease2.99 (0.7–12.7)0.139  
  1. MAP mean arterial pressure, ICU intensive care unit, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident
  2. Statistically significant data are italicized